A decade of bariatric surgery. What have we learned? Outcome in 520 patients from a single institution  by Musella, M. et al.
lable at ScienceDirect
International Journal of Surgery 12 (2014) S183eS188Contents lists avaiInternational Journal of Surgery
journal homepage: www.journal-surgery.netOriginal researchA decade of bariatric surgery. What have we learned? Outcome in 520
patients from a single institution
M. Musella a, *, M. Milone a, D. Gaudioso a, P. Bianco a, R. Palumbo a, G. Galloro b,
M. Bellini a, F. Milone a
a
“Federico II” University, Medical School, Advanced Biomedical Sciences Department e General Surgery, Italy
b Clinical Medicine and Surgery Department e Surgical Endoscopy, Italya r t i c l e i n f o
Article history:
Received 23 March 2014
Accepted 3 May 2014
Available online 23 May 2014
Keywords:
Bariatric surgery
Laparoscopic adjustable gastric banding
Laparoscopic sleeve gastrectomy
Laparoscopic mini gastric bypass
Intragastric balloon
Outcome* Corresponding author. “Federico II” University, A
Department, AOU “Federico II”, Via S. Pansini 5, Build
E-mail address: mario.musella@unina.it (M. Muse
http://dx.doi.org/10.1016/j.ijsu.2014.05.012
1743-9191/© 2014 Surgical Associates Ltd. Publisheda b s t r a c t
Background: Today a variety of bariatric surgical procedures is available and, currently, it is difﬁcult to
identify the most effective option based on patient characteristics and comorbidities. Aim of this
retrospective study is to evaluate the efﬁcacy of four different techniques; Intragastric Balloon (IB),
Laparoscopic Adjustable Gastric Banding (LAGB), Laparoscopic Sleeve Gastrectomy (LSG) and Laparo-
scopic Mini Gastric Bypass (LMGB), performed in our unit along ten years.
Patients and methods: Starting from January 2005, 520 patients, 206 men (39.6%) and 314 women (60.4%)
were treated at our institution. Among patients candidate to bariatric surgery 145 underwent IB, 120
underwent LAGB, 175 underwent LSG and 80 underwent LMGB. Follow up rate was 93.1% for IB at 6
months; 74.1% and 48% for LAGB at 36 and 60 months respectively; 72.8% and 58.1% for LSG at 36 and 60
months respectively; and 84.2% for LMGB at 36 months.
Results: The period 2005e2014 has been considered. Mortality was 1/520 patients (0.19%). The excess
weight loss rate (EWL%) has been 32.8 for IB at six months, 53.7 for LAGB and 68.1 for LSG, at 60 months
respectively and 79.5 for LMGB at 36 months. Early major postoperative complications requiring surgery
were 0.6% for IB and 1.1% for LSG whereas late major postoperative complications were 1.2% for IB, 4.1%
for LAGB and 0.5% for LSG. Diabetes resolution rate was 0 for LAGB, 76.9% for LSG and 80% for LMGB at 36
months.
Conclusions: If more invasive procedures as LSG or LMGB may entail higher operative and peroperative
risks, conversely, in skilled hands their efﬁcacy remains undisputed, especially in the long term, pre-
senting a very low rate of major complications. In general, the efﬁcacy of a bariatric surgery unit seems
improved by the capability to offer both different primary procedures and re-do surgery.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Obesity is a pandemic health problem in both developed and
developing countries and the costs of care continue to grow in
parallel with the prevalence of the disease. This morbid condition
leads to a high incidence of complications and a decrease in life
expectancy, especially among younger adults [1,2]. In fact it is
associated with development of comorbid conditions such as hy-
pertension, diabetes mellitus, sleep apnea, congestive heart failure
and certain tumor [3]. Moreover, obese women of reproductive agedvanced Biomedical Sciences
ing 12, 80131 Naples, Italy.
lla).
by Elsevier Ltd. All rights reservedare a speciﬁc group at risk for obesity-related reproductive and
obstetric complications [4]. Particularly there is a strong association
between obesity and infertility, and weight loss can result in
increased fecundity in obese women [5,6]. So, while the obesity
epidemic continues to increase worldwide, surgery remains the
only proven treatment modality [7]. Today a variety of surgical
procedures is available and, currently, it is difﬁcult to identify the
most effective option based on patient characteristics and
comorbidities.
Intragastric balloon (IB) treatment is an endoscopic approach
less invasive than surgery. It promotes a weight loss of ﬁve to nine
body mass index (BMI) units in 6e12 months with an impressive
improvement of obesity-associated comorbidities [8,9] in all those
patients not yet suitable, or deﬁnitely not suitable for surgery, due
to different reasons..
Table 1
Patient demographics and comorbidities.
Procedure IB
(n ¼ 145)
LAGB
(n ¼ 120)
LSG
(n ¼ 175)
LMGB
(n ¼ 80)
Mean age (range) 35.4
(18e60)
39.5
(18e66)
38.2
(19e58)
34.8
(17e55)
Sex, male ratio to 1 female 0.59 0.6 0.42 1.08
Mean BMI kg/m2
a
(range) 55.4
(48e74)
42.3
(29e57)
47.9
(38e63)
50.8
(41e67)
Co-morbidities (sub-group analysis)
Type 2 diabetes mellitus (n) 42 1 26 25
Hypertension (n) 48 20 37 3
Hyperlipidemia (n) 48 0 7 0
Obstructive sleep apnea (n) 21 1 7 0
Arthrosis (n) 52 8 22 3
Infertility (n) 34 43 34 14
a At the time of operation. BMI, body mass index; IB, Intragastric Balloon; LAGB,
Laparoscopic Adjustable Gastric Banding; LMGB, Laparoscopic Mini Gastric Bypass;
LSG, Laparoscopic Sleeve Gastrectomy.
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methods for surgical treatment of morbid obesity. In 1986, Kuzmak
et al., developed a silicone band with an inﬂatable inner balloon
that could be adjusted percutaneously by adding or removing sa-
line via a subcutaneous reservoir connected to the adjustable band
[10]. Vincent modiﬁed the Kuzmak adjustable gastric band for use
laparoscopically, and in September 1993, the ﬁrst laparoscopic
bariatric procedure was performed by Belachew et al. in Belgium
[11]. LAGB is perceived as a safe, minimally invasive, fully reversible
and adjustable procedure [12,13].
Laparoscopic sleeve gastrectomy (LSG) was introduced as a ﬁrst-
step procedure to minimize surgical risk for super-super-obese or
high-risk patients, followed by either laparoscopic biliopancreatic
diversionwith duodenal switch (BPD-DS) or laparoscopic Roux-en-
Y gastric bypass (LRYGBP). Afterward it was noticed that the sleeve
gastrectomy alone caused good weight loss before the second part
was performed. So the encouraging results obtained in some series,
have led many authors to avoid a second surgical intervention,
especially if the excess weight loss percentage (EWL%) of operated
patients reached and maintained satisfactory levels [14,15].
The laparoscopic mini-gastric bypass (LMGB) was introduced by
Rutledge in 1997 and reported some years later [16]. Since then,
thousands of patients have been treated with this approach by
several authors in different countries [17e23]. When presented,
MGB raised harsh criticism [24], but despite that skeptical position,
different authors have reported interesting results in terms of
weight loss and resolution of obesity related comorbidities,
describing a low rate of mid- and long-term postoperative com-
plications even outperforming LRYGBP in some studies [25,26].
Finally, recent results are encouraging regarding the effectiveness
of mini-gastric bypass on diabetes remission [27e29]. Aim of this
review is to evaluate the efﬁcacy of these four procedures in our
institution (IB, LAGB, LSG and LMGB) in determining permanent
weight loss and resolution of comorbidities. Complication and
failure rate for each procedure (IB, LAGB, LSG and LMGB) at 12, 36
and 60 months are reported as well.
2. Patients and methods
Starting from January 2005, 520 patients, 206 men (39.6%) and
314 women (60.4%) were evaluated at our institution by a multi-
disciplinary team and then submitted to bariatric surgery following
the Italian Society for Bariatric and Metabolic Surgery (SICOB)
guidelines [30]. Patients scheduled to LSG and LMGB received a
preoperative esophago-gastro-duodenoscopy (EGDS) and a routine
preoperative Helicobacter Pylori screening. Among patients
candidate to bariatric surgery 145 underwent IB, 120 underwent
LAGB, 175 underwent LSG and 80 underwent LMGB.
For all patients, informations on demographics, pre-operative
and post-operative body mass index, and pre-operative co-mor-
bidities were recorded at hospitalization, see Table 1, while data
regarding improvement or resolution of co-morbidities, weight loss
expressed as the percentage of excess weight loss (EWL%) and long-
term complications were recorded during follow-up. All data were
stored in a prospectively collected bariatric surgery database. A
follow-up examination, when possible, was made at 1, 3, 6, 12, 24,
36 and 60 months after the surgery. All the patients received an
antipulmonary thromboembolism (PE) prophylaxis according to
SICOB guidelines [30]. Perioperative antiplatelet drugs adminis-
trationwere managed according to validated criteria [31]. One dose
of 2 g ceftriaxone was administered intravenously 10e15 min
before the operation for infection prophylaxis. In all but 1 case
(0.24%), patients were approached by laparoscopy. All patients
submitted to LAGB, LSG, LMGB and 58/145 (40%) patients treated by
IB, underwent general anesthesia. Two endoscopists performed allIB procedures while surgery was performed by one single surgeon.
Statistical analysis was performed with SPSS version 14.0 (SPSS©,
Chicago, IL, USA).
2.1. Surgical technique
2.1.1. IB
In 135/145 cases (93.1%) a Bioenterics Intragastric Balloon (BIB®,
Inamed Health-Allergan, Santa Barbara, CA, USA) was the device of
choice. BIB placement was performed under slight sedation as an
outpatient procedure in 87 patients (60%) as described in our
previous paper [32], and the BIB was inﬂated under direct vision
with a mixture of 500e550 mL saline and 10e20 mL of methylene
blue. Mean operative time was 22 ± 5.4 min. After full recovery
from sedation, patients were discharged. They are usually given
proton pump inhibitor (PPI) for 7 days and antiemetic drugs as
needed. Follow-up consultation with a dietician is recommended
after BIB placement. The balloon is routinely removed under EGDS
6 months after BIB placement.
2.1.2. LAGB
The LAGB procedure was performed using four to ﬁve operative
ports positioned in the upper abdomen [33]. The ﬁrst step consisted
of locating and releasing the left pillar. A small opening is made in
the pars ﬂaccida towards the gastro-hepatic ligament, thus allow-
ing location of the right pillar. A narrow passage is then created
above the lesser sac in the gastrophrenic ligament to the angle of
His. The AGB, introduced using a 10/15-mm port, is then positioned
around the stomach. The band is closed below a small calibration
balloon, which had been inﬂated (20 mL) in the stomach. This
calibration step has been performed in the ﬁrst 30 patients only.
The anterior part of the band is covered using three gastroegastric
sutures to minimize the risk of slippage. The reservoir has been
positioned before the abdominal muscular aponeurosis in the ﬁrst
twenty patients, later it has been placed in the subcutaneous fat of
the left lower abdominal quadrant. In 85/120 cases (70.8%) a SAGB
BD2XV or a newer BD3XV band (SAGB®, Ethicon Endo-Surgery,
Johnson & Johnson©, Somerville NJ, USA) were used, while in the
remaining patients a different device (Lap Band AP System®,
Inamed Health-Allergan, Santa Barbara, CA, USA) was used. Mean
operative time was 55 ± 15.6 min. Patients were routinely dis-
charged on postoperative day (POD) 2.
2.1.3. LSG
As reported [34] following the preparation of the greater cur-
vature, a gastric sleeve is tailored using a 60 mm linear stapler
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Somerville NJ, USA) following the edge a 38F calibrating oro-gastric
tube. A total of ﬁve to seven cartridge is used. Between the closure
of the stapler and its ﬁring, a 20 s interval has been observed in any
case. Although debated, no oversewing of the staple line is per-
formed to prevent bleeding or staple line leaks [14,34]. Amethylene
blue test with 80e100 mL of saline solution is routinely performed
to evaluate possible leaks. In all patient a naso-gastric tube and a
drainage tube are left in place. Mean operative time was
75 ± 15.3 min. The nasogastric tube is removed on POD 1 and liquid
diet assumption is allowed starting on POD 3 provided the patient
has ﬂatus passage. On the same day, an upper GI series with Gas-
trographin® has been routinely performed in the ﬁrst 50 patients.
Later only an abdominal CT scanwas scheduled if clinical symptoms
(fever, tachycardia, leukocytosis, pain) were present. Patients are
routinely discharged on POD 5.
2.1.4. LMGB
The technique used for LMGB has been described [23]. A
14e16 cm long gastric tube is created using a 60 mm stapler
(Echelon ﬂex 60®, Ethicon Endo-Surgery, Johnson & Johnson©,
Somerville NJ, USA) starting on the lesser curvature at the crow's
foot level. It is tailored following the edge of a 38F calibrating oro-
gastric tube up to the angle of His. A loop gastroenterostomy is then
created with the small bowel about 200 cm distal to the ligament of
Treitz with the same stapler using a 60 mm blue cartridge. The
gastrojejunal anastomosis is then closed with a double-layer self
locking running 2e0 suture [35]. A reinforcement of the suture line
is obtained by ﬁbrin sealant. All patients are checked by an intra-
operative methylene blue test at the end of the procedure. Two
drain tubes are placed in all the patients. Mean operative time was
115 ± 15.6 min. No routine contrast X-ray is performed. As for LSG,
only an abdominal CT scan is scheduled if clinical symptoms are
present. Following the nasogastric tube removal on POD 1, a liquid
diet is started for all the patients on POD 3. Drains are removed at
discharge on POD 5.
2.2. Follow-up
Postoperatively, patients are followed by a multidisciplinary
team, and outpatient clinic visits are scheduled once a month for
the ﬁrst 3 postoperative months and every 3 months thereafter.
IB patients are routinely checked by ultrasound at 1 and 3
months following BIB placement. Radiology or EGDS examination is
scheduled if clinically indicated in patients submitted to LMGB, LSG
or LAGB. Patients submitted to LMGB have been to date examined
by EGDS one and three year after operation. Regarding to patients
submitted to LAGB, adjustments to the band are performed ac-
cording to manufacturer's guidelines. An early complication is
deﬁned as a complication that occurs within 30 days post-
operatively. A major complication is deﬁned as a complication that
requires interventional management and hospitalization for moreTable 2
Weight loss and resolution rate of comorbidities at 12, 36 and 60 months (mos) of follow
Procedure IB(n ¼ 145) 6 mos LAGB (n ¼ 120)
12 mos 36 mos 60 mos
Follow-up (%) 93.1 90.8 74.1 48
Mean BMI (kg/m2) 41.7 33.5 31.8 33.3
EWL (%) 32.8 53.5 58.2 53.7
Type 2 DM (%) 50 0 0 0
Hypertension (%) 70 85 82 72.4
OSA (%) 95 100 e e
Arthrosis (%) 89 100 e e
Infertility (%) 63.5 e 63.7 ethan 14 days. Complications related to the operation that occur
later than 30 days postoperatively, and require readmission, are
deﬁned as late complications. EWL%, BMI decrease, glycemic status,
and blood arterial pressure (BP) were assessed. Remission of T2DM
was deﬁned as glycated hemoglobin (HbA1c) less than 6.5% in the
absence of hypoglycemic drugs [28]. Remission of hypertension
was deﬁned as the discontinuation of antihypertensive therapy.
Remission of arthrosis or joint impairment was deﬁned as the
discontinuation of FANS or steroids assumption.
3. Results
The period 2005e2014 has been considered. Mortality was 1/
520 patients (0.19%). It was a 25 years old female super-obese pa-
tient presenting a massive postoperative PE later followed by a
disseminated intravascular coagulation (DIC) following a LSG.
Table 2 reports weight loss and resolution comorbidity rate for all
four procedures. The outcomes are distributed in different period of
follow up for the surgical procedures (LAGB, LSG, LMGB). No sig-
niﬁcant difference has been noticed in terms of early or late com-
plications, or outcomes by using different brand of AGB (p ¼ n.s.).
The drop out rate at 12, 36 and 60 months was not signiﬁcantly
different between the surgical procedures (p ¼ n.s). Table 3 reports
the complications rate in the peroperative period or during the
follow up. They are classiﬁed as major or minor complications. Data
at 60 months for LMGB are not yet available. EWL % for LMGB has
been signiﬁcantly higher than EWL% for LAGB and LSG at 36
months (p < 0.03). Table 4 reports the rate of bariatric surgical
procedures per year in our department whereas table 5 considers
the changes of bariatric procedures performed in the same period
in our unit.
4. Discussion
Morbid obesity surgery has evolved dramatically. This rapid
growth reﬂects the ability of bariatric surgery to achieve major and
durable weight loss, as well as the evolution of safer, less invasive
procedure. In this direction Table 4 reports the growing role of
bariatric surgery in our department. Three of the most common
procedures performed today are IB, LAGB and LSG. LMGB, although
some criticism, is deﬁnitely gaining worldwide popularity [16e29].
Intragastric balloon treatment, less invasive than surgery, pro-
motes a weight loss of ﬁve to nine BMI units in 6 months with an
impressive improvement of obesity-associated comorbidities [36]
in all those patients not suitable for surgery due to different rea-
sons. Our experience conﬁrms it remains the most effective “bridge
to surgery” option [37], allowing surgeons and patients to approach
surgery with a decreased operative risk. Our data show in fact a
mean decrease of 8.7 BMI units, in patients candidate to different
bariatric surgical procedures.
Conversely LAGB, although remaining a safer bariatric proce-
dure [11,38], is experiencing a loss in conﬁdence from many-up.
LSG (n ¼ 175) LMGB (n ¼ 80)
12 mos 36 mos 60 mos 12 mos 36 mos 60 mos
93.8 72.8 58.1 93.7 84.2
32.6 29.4 29.7 29.2 27.5 e
61.4 68.3 68.1 72.1 79.5 e
80.7 76.9 65.3 88 80 e
85 90 90 95 92 e
100 e e e e e
92 92 92 100 e e
e 65.7 e e 70.6 e
Table 3
Complication rate.
Procedure IB
(n ¼ 145)
LAGB
(n ¼ 120)
LSG
(n ¼ 175)
LMGB
(n ¼ 80)
Conversion rate to open
surgery n (%)
1 (0.6)a 1 (0.8) 0 1 (1.2)
Early postoperative
Complications n (%)
Major 0 0 2 (1.1)d 0
Minor 0 0 4 (2.2) 1 (1.2)
Late postoperative
complications n (%)
Major 2 (1.2)b 5 (4.1)c 1 (0.5)e 0
Minor 0 15 (12.5)f 19 (10.8)f 3 (3.7)
a Requiring IB removal followed by open RYGB.
b Severe Esophagitis Requiring IB removal.
c Requiring AGB removal.
d One death.
e Wernicke Syndrome.
f GERD managed with proton pump inhibitors (PPI).
Table 4
Rate of bariatric surgery procedures/major
general surgery procedures per year in our
department.
2005 5%
2006 6.5%
2007 7.5%
2008 10%
2009 14.5%
2010 22.6%
2011 20%
2012 25%
2013 25.5%
Table 5
Shift of surgical procedures along the years.
IB LAGB LSG LMGB Total
2005 29 e e e 29
2006 25 10 e e 35
2007 24 12 e e 36
2008 26 18 6 e 50
2009 10 21 16 4 51
2010 9 26 26 13 74
2011 5 12 30 15 62
2012 4 10 44 18 76
2013 8 9 42 22 81
2014 (February) 5 2 11 8 26
Total 145 120 175 80 520
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term remain controversial, with a high failure rate. To date, out-
comes for LAGB appear deﬁnitely less encouraging when compared
to LSG, RYGBP or BPD [38e41]. This trend is conﬁrmed in our
experience, see Table 5. In our series LAGB provides amean BMI loss
of 15.9 units, with an overall removal rate of 4.1% and a good res-
olution rate for hypertension and arthrosis, see Tables 2 and 3.
Nevertheless, starting from 2008, patients presenting a BMI higher
than 45 or diabetes, have been routinely excluded from receiving
AGB in our unit. In these years we have modiﬁed our technique by
placing the regulation port in subcutaneous tissue without ﬁxation
to muscular aponeurosis. It allows reaching it without X-ray sup-
port. It may be of great help in those patients requiring frequent
adjustments of the band.
LSG is usually considered a restrictive procedure even though
some other advantages have been observed when compared to
other interventions. They are the hormonal effect produced by theghrelin and the glucagon-like peptide 1 (GLP-1) decrease, the
accelerated gastric emptying, the absence of implanted material,
the persistence of normal gastrointestinal continuity, the preser-
vation of gastric antrum in order to allow sufﬁcient production of
intrinsic factor, the avoidance of malabsorption, and ﬁnally the
opportunity to convert LSG into both a LRYGBP or a BPD-DS
[15,42,43]. On the other hand while leaks remain a worrisome
complication, difﬁcult to be managed, a proper surgical strategy
may signiﬁcantly reduce their occurrence [44]. Although nutri-
tional issues must be carefully evaluated [45], the analysis of our
experience with LSG indicates that this is an effective and safe
procedure for the treatment of morbid obesity. The early and long
term complication rate and the 5 years result seems to be in line
with previous papers [15,38,42e44], see Tables 2 and 3. The rela-
tionship between LSG and GERD remains on the other hand an
interesting point of debate. It remains unclear how LSG can affect
the lower esophageal sphincter physiology in the long term
[46e48]. In our series a 10.2% of patients complain of GERD in the
long term following LSG. As previously reported [49], and due to 3/
3 (100%) false negative for leak, routine upper GI series with Gas-
trographin® has been abandoned, in our unit, in favor of selective
CT scan to be performed if clinical symptoms are present.
LMGB offers several advantages. It is reported as a short, simple,
low-risk, effective, and durable procedure, meeting many of the
criteria of an ideal weight loss surgery [16]. Nevertheless, different
key points as gastric and esophageal bile reﬂux, marginal ulcers,
and long-term risk for gastric/esophageal cancer, despite the
increasing number of articles reporting good results
[17e23,27e29], continue to be a matter of debate [50,51]. In our
opinion, although technical simplicity or shorter operative time are
unquestionable issues while choosing an intervention, LMGB
should be preferred to other bariatric approaches, RYGB and SG
included [22,25,27], for the positive results reported in terms of
efﬁcacy in the treatment of morbid obesity and comorbidities
resolution in both short and long term [23,28]. EWL% provided by
LMGB has been signiﬁcantly higher than the values offered by LAGB
and LSG. These data appear especially interesting if we consider
that patients were selected to different procedures considering
their preoperative BMI. Usually, higher BMI patients were sched-
uled to LSG or LMGB only. In conclusion, whereas more invasive
procedures as LSG or LMGB may entail higher operative and per-
operative risks, conversely, in skilled hands their efﬁcacy remains
undisputed, especially in the long term. In general, the efﬁcacy of a
bariatric surgery unit seems improved by the capability to offer
both different primary procedures and re-do surgery. Such con-
cepts emerging by our experience, appears to be conﬁrmed bymost
recent scientiﬁc literature as well.
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